Trial Profile

RTA 402 Phase 3 Clinical Trial (A Randomized, Double-blind, Placebo-controlled Clinical Trial in Patients With Diabetic Kidney Disease)

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 28 Sep 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bardoxolone methyl (Primary)
Indications Diabetic nephropathies
Focus Therapeutic Use
Acronyms AYAME
Sponsors Kyowa Kirin

Most Recent Events

10 May 2023 Status changed from active, no longer recruiting to discontinued.according to a Kyowa Kirin Co media release.
10 May 2023 According to a Kyowa Kirin Co media release, based on the data of this study and after discussions with key opinion leaders and PMDA, the company has determined that it is difficult to file an application for manufacturing and marketing approval of RTA 402 for diabetic kidney disease in Japan and decided to discontinue the development for this indication.
10 May 2023 Results presented in a media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com